Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Authors:

Abstract
The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Small-molecule inhibitors, as the alternative to monoclonal antibodies are expected to overcome the disadvantage of mAbs which include production difficulties and their long half-life. Recently, progress has been reported on anti-PD-1/PD-L1 small-molecule inhibitors. In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-molecule inhibitors. The structures and the preclinical and clinical studies of several peptide-based small-molecule candidate compounds in clinical trials are discussed. We also illustrate the design strategies underlying reported nonpeptidic small-molecule inhibitors and provide insight into possible future exploration. Development of small-molecule drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect.
Funding Information
  • Ministry of Science and Technology of the People's Republic of China (2018ZX09301045002)
  • Chinese Pharmaceutical Association
  • National Natural Science Foundation of China (21472191, 81773559)
  • Guangzhou Municipality (201704030099)
  • Guangdong Province (2013A022100019, 2016A050502036)
  • Yiling Biopharmaceutical Innovation Foundation

This publication has 80 references indexed in Scilit: